Invasive tubular carcinoma is a morphologically distinct subtype of carcinoma with a favorable outcome compared with grade 1 ductal carcinoma. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The excellent prognosis of tubular carcinoma stems from studies in which most patients were treated with mastectomy and were compared with patients with ductal carcinomas that were several centimeters larger. We recently completed a complete pathologic review of 607 invasive breast carcinomas from 583 patients treated with breast-conserving therapy at our institution and found invasive carcinoma morphologic features were not associated independently with outcome. 14 This prompted us to question whether patients with tubular carcinoma continued to have significantly better outcomes than patients with grade 1 ductal carcinoma among contemporary breast carcinoma patients treated with breast-conserving therapy.
Invasive tubular carcinoma is a morphologically distinct subtype of carcinoma with a favorable outcome compared with grade 1 ductal carcinoma. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The excellent prognosis of tubular carcinoma stems from studies in which most patients were treated with mastectomy and were compared with patients with ductal carcinomas that were several centimeters larger. We recently completed a complete pathologic review of 607 invasive breast carcinomas from 583 patients treated with breast-conserving therapy at our institution and found invasive carcinoma morphologic features were not associated independently with outcome. 14 This prompted us to question whether patients with tubular carcinoma continued to have significantly better outcomes than patients with grade 1 ductal carcinoma among contemporary breast carcinoma patients treated with breast-conserving therapy.
The definition of tubular carcinoma is not precise. Authors have allowed 0% to 25% admixture of usual-type ductal carcinoma. 3, 4, 6, 8, 10, 11, [15] [16] [17] Furthermore, it often is difficult to determine whether an individual duct is sufficiently "tubular" in appearance to qualify as tubular carcinoma. Invasive ductal carcinomas with some but not all morphologic features of tubular carcinoma are common. 18 These morphologic issues recently were addressed in a study in which the authors found tubularity percentage, defined as the proportion of neoplastic cells that were adjacent to open lumens, nuclear grade, and mitoses, could be used to separate tubular and ductal carcinomas. 18 Invasive carcinomas with more than 70% tubularity, grade 1 nuclei, and very rare mitoses had no lymph node metastases or breast carcinoma-associated deaths. To our knowledge, the prognostic strength of these morphologic criteria has not been examined by another group of authors and compared with standard criteria for tubular carcinoma.
The goals of this study were to evaluate whether tubular carcinoma continued to have a more favorable prognosis than grade 1 ductal carcinoma in contemporary breast carcinoma patients and to compare the prognostic strength of the recently proposed tubular carcinoma criteria with standard criteria.
Materials and Methods

Clinical Data
This study consisted of the 147-case subset of all tubular and grade 1 ductal carcinoma cases among 607 patients with American Joint Committee on Cancer stage I/II, consecutively treated with breast-conserving therapy at William Beaumont Hospital, Royal Oak, MI, from January 1980 to December 1996. The slides for the 147 patients were rereviewed for the present study according to their accession date, and the additional parameters used in this study were recorded before reviewing the surgical pathology report.
Outcome analyses of factors pertaining to the overall patient cohort were reported previously. 14 The outcome for the current patient population was updated from the William Beaumont Hospital Tumor Registry. All 147 invasive carcinomas were treated in a similar manner consisting of an initial lumpectomy/partial mastectomy with the intention of complete resection. None of the patients with carcinoma underwent a needle core biopsy before excision. Patients underwent reexcision of the primary tumor site for inadequate margin distances or questionable postsurgical mammography results at the discretion of the surgeon or radiation oncologist. All patients received standard doses of postoperative radiation therapy with boost to the tumor bed. The median total radiation therapy and tangent doses were 61.0 Gy and 45.0 Gy, respectively. The total radiation therapy dose was not adjusted for tumor grade, dimension, or margin status.
Of the neoplasms, 32 (21.8%) were pure tubular carcinomas (standard morphologic criteria) and 115 (78.2%) were grade 1 ductal carcinomas. The mean and median follow-up periods for the 147 patients were 10.4 and 10.5 years, respectively (range, 1.1-22.3 years).
An ipsilateral breast failure was defined as a distinct invasive carcinoma in the treated breast after the completion of radiation therapy. Regional metastases were defined as metastases to ipsilateral axillary, internal mammary, or supraclavicular lymph nodes. Distant metastases were defined as metastases to sites other than those included in the definition of regional metastases. Disease-free survival was the time interval between completion of radiation therapy and the date of diagnosis of ipsilateral breast failure or metastasis (regional or distant).
Pathologic Features
All slides from every breast resection specimen and axillary lymph node dissection were reviewed by one of us (N.S.G.). Factors recorded in each case were as follows:
1. Tubular carcinoma percentage, quantified in deciles: Tubular carcinomas had haphazardly arranged, infiltrative ducts that were well formed, relatively uniform in size, and separated by abundant desmoplastic fibrous stroma ❚Image 1❚, ❚Image 2❚, and ❚Image 3❚. 1, 3, 4, 7, 8, 15, 19, 20 The caliber of most ❚Image 1❚ Tubular carcinoma. The neoplasm is composed of widely dispersed, uniform-sized, oval to elongated dilated ducts (H&E, ×16).
❚Image 2❚ Tubular carcinoma (higher magnification of Image 1). The ducts are evenly dispersed throughout the stroma. Some have tapered, pointed ends (H&E, ×40) widely patent tubular carcinoma ducts did not vary between the center and periphery of the neoplasm. Ducts formed elongated branching tubules or small, round or oval glands with sharply pointed or teardrop-or prow-shaped outlines. Longitudinally, the tubules seemed to bud from a central segment. Tubular carcinoma cells were slightly larger than those lining adjacent normal ducts and cuboidal to slightly elongated. Nuclei were round to oval with no pleomorphism. Cells had uniform nuclear membranes, homogeneous and finely granular chromatin, and punctate nucleoli. Most cells had moderate amounts of eosinophilic cytoplasm with an irregular cytoplasmic luminal surface (apocrine snouts).
Invasive grade 1 ductal carcinomas were defined by the absence of the morphologic features of tubular carcinoma. [21] [22] [23] Ductal carcinoma ducts had smooth, symmetrical outlines without sharply angulated ends. Ducts in the center of carcinomas frequently were more compressed and smaller than peripherally situated ducts. Ductal carcinoma cells usually had no apocrine snouts. Variable numbers of admixed cells with moderate (grade 2) nuclear heterogeneity were characteristic ❚Image 4❚, ❚Image 5❚, and ❚Image 6❚. 3. Invasive carcinoma grade: The criteria of the Elston and Ellis modified Bloom-Richardson grading scheme were applied strictly to each carcinoma. 24, 25 Careful attention was given to scoring criteria to avoid underscoring and overscoring. 26 Scoring was done on sections cut from adequately fixed tissue. 27 4. Invasive carcinoma nuclear grade heterogeneity: Carcinomas were classified as pure, uniform grade 1 nuclei, or predominantly grade 1 nuclei with occasional grade 2 nuclei.
5. Final margin status: The final margin status was known in all 147 cases. Final margin status categories were as follows: negative, invasive carcinoma and ductal carcinoma in situ (DCIS) situated more than half a low-power field (LPF) from the margin; near, invasive carcinoma or DCIS located half an LPF or less from the margin but not at the margin; and positive, invasive carcinoma or DCIS transected by the inked margin. Near the margin was the 4.2-mm-wide rind of parenchyma adjacent to the final margin. This width was half of an LPF visual field diameter using the 4× objective and 10× ocular lenses of the reviewing author's (N.S.G.) microscope.
6. Amount of carcinoma near the final margin: Cases in the near final margin category were stratified based on the amount of invasive carcinoma and DCIS in the parenchyma near the final margin. The 3 carcinomaamount categories were least amount, less than 3 mm of composite width of invasive carcinoma and fewer than 13 DCIS ducts near the final margin; intermediate amount, 3 mm or more composite width of invasive carcinoma and fewer than 13 DCIS ducts near the margin; and greatest amount, 13 or more DCIS ducts and any width of invasive carcinoma near the margin. The cut points for the 3 carcinoma-amount categories were established by using the entire 607 case database and have been reported in detail elsewhere. 14 7. Final margin status-amount of carcinoma near margin (combined factor): The 3 carcinoma-amount subcategories in the near final margin category were merged with the final margin status, which resulted in the following 5-tiered combined factor: (1) negative margin; (2) near margin, least amount of carcinoma; (3) near margin, intermediate amount of carcinoma; (4) near margin, greatest amount of carcinoma; and (5) positive margin. This combined factor was associated independently with increasing risk of ipsilateral breast failure and distant metastases in the 607-case overall data set. 14 8. Axillary lymph node dissection-related factors: All 147 patients underwent ipsilateral axillary dissection. The number of axillary lymph nodes examined, number of lymph nodes with metastases, and maximum dimension of the largest metastasis was recorded in each case.
9. Additional factors: The maximum dimension of invasive carcinoma, number of slides with DCIS, vascular space invasion, and maximum dimension of specimen were included.
All time intervals were calculated from the date of the initial surgery. Estimated likelihood of events for ipsilateral breast failure, contralateral breast carcinoma, and distant metastases were calculated by using the Kaplan-Meier method. Associations between factors were analyzed by using the Fisher exact test (2-tailed) and logistic-linear regression. Associations between clinical, pathologic, and ❚Image 9❚ Tubular carcinoma. Tubularity percentage of field, 85%. The majority of ducts have tubularity percentages of more than 95%. Several ducts have centrally situated nonluminal cells, which slightly reduces the overall tubularity percentage of the field. This was the standard magnification used to assess the tubularity percentage (H&E, ×80). treatment-related variables and clinical events were analyzed by using logistic regression and Cox regression. Statistical associations between actuarial outcomes and their associated survival curves were calculated with the log-rank test and the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards model. Statistical analysis was performed by using the Systat statistics computer program, version 10.2 (Systat Software, Point Richard, CA).
Results
The mean maximum dimensions of tubular and ductal carcinomas were 0.95 cm and 1.1 cm, respectively (P = .067) ❚Table 1❚. The mean patient ages, amount of carcinoma near the margin, final margin status, and reexcision rates were also similar. The proportion of cases with axillary lymph node metastases in the 2 carcinoma groups was similar (Table 1) . However, the mean number of lymph node metastases was significantly greater among patients with ductal carcinoma than those with tubular carcinoma, and the mean maximum dimension of the lymph node metastases was significantly larger in ductal carcinomas than in tubular carcinomas (Table 1) .
Tubular Carcinoma, Tubularity, and Tubularity-Nuclear Grade
Of the 147 patients, 19 (12.9%) sustained ipsilateral breast failures and 14 (9.5%) developed distant metastases ❚Table 2❚. Of the 32 patients with pure tubular carcinoma, 1 patient (3%) sustained an ipsilateral breast failure and 2 (6%) developed distant metastases.
The tubularity percentage was similar but did not correspond precisely to the percentage of tubular carcinoma. Of the 32 pure tubular carcinomas, 16 (50%) had 60% to 69% tubularity, 9 (28%) had 70% to 79% tubularity, 9 (28%) had 80% to 89% tubularity, and 6 (19%) had tubularity of 90% or more. Overall, 122 (82.9%) of 147 carcinomas had less than 70% tubularity and 25 (17.0%) had tubularity of 70% or more. 18 Of the 25 carcinomas with tubularity of 70% or more, 16 had predominantly grade 1 nuclei, occasional grade 2 nuclei, and occasional mitoses and 9 had only grade 1 nuclei and rare mitoses.
Ipsilateral Breast Failure
Eleven (58%) of 19 ipsilateral breast failures and 12 (86%) of 14 distant metastases occurred in patients with invasive carcinomas with less than 70% tubularity. The remaining 8 ipsilateral breast failures (42%) and 2 distant metastases (14%) occurred in patients with carcinomas with tubularity of 70% or more, occasional grade 2 nuclei, and occasional mitoses. None of the patients with invasive carcinomas with tubularity of 70% or more, pure nuclear grade 1, and rare mitoses developed an ipsilateral breast failure or distant metastases.
Factors associated with ipsilateral breast failure were the tubularity-nuclear grade (P < .001) and the combined factor (margin status-amount of carcinoma near margin) (P < .001) ❚Table 3❚. An increasing percentage of tubular carcinoma in the invasive carcinoma was not associated with ipsilateral breast failure (P = .462).
The overall mean and median intervals until ipsilateral breast failure were 9.1 and 9.2 years, respectively (range, 5.8-16.4 years; SD, 4.8 years). The mean intervals were 8.7 years for patients with invasive carcinomas with less than ဲ 70% tubularity and 13.8 years for patients with invasive carcinomas characterized by tubularity of 70% or more and occasional grade 2 nuclei (P < .001).
The 10-year ipsilateral breast failure rates for patients with invasive carcinoma with negative margins; near margins, least amount of carcinoma; near margins, intermediate amount of carcinoma; near margins, greatest amount of carcinoma; and positive margins were 0%, 0%, 8%, 21%, and 37%, respectively (P < .001) ❚Table 4❚. The 10-year actuarial ipsilateral breast failure rates for invasive carcinomas with less than 70% tubularity, 70% or more tubularity and occasional grade 2 nuclei, and 70% or more tubularity and pure grade 1 nuclei were 13%, 9%, and 0%, respectively. The differences in failure rates between the 3 
ဲ ဲ ဲ
tubularity-nuclear groups were significantly different (P < .001); however, the failure rates of patients with invasive carcinoma with less than 70% tubularity vs carcinoma with tubularity of 70% or more and occasional grade 2 nuclei were not significantly different (P = .422). An increasing percentage of tubular carcinoma was not associated significantly with lower 10-year ipsilateral breast failure rates (P = .462).
In multivariate analysis, the margin status-amount of carcinoma near margin combined factor (P < .001; hazard ratio = 5.812) and tubularity-nuclear grade factor (P < .001; hazard ratio = 5.219) were associated independently with ipsilateral breast failure.
Distant Metastases
Distant metastases developed in 14 patients (9.5%). The mean and median intervals until distant metastases were 7.7 and 8.9 years, respectively (range, 1.3-15.9 years). The 5-and 10-year actuarial distant metastases rates for all patients were 3% and 9%, respectively. The 10-year distant metastases rates for patients with pure ductal and tubular carcinomas were 11% and 8%, respectively (P = .082) ❚Table 5❚. The 10-year distant metastases rates for patients with invasive carcinomas with less than 70% tubularity, 70% or more tubularity and occasional grade 2 nuclei invasive carcinomas, and 70% or more tubularity and pure grade 1 nuclei were 14%, 6%, and 0%, respectively (P = .028). Axillary lymph node metastases also were associated significantly with lower 10-year distant metastases rates (P = .002).
In multivariate analysis, tubularity-nuclear grade (P < .001; hazard ratio = 4.647) and axillary lymph node metastases (P < .001; hazard ratio = 3.366) were associated independently with distant metastases.
Survival Rates
The 10-year disease-free survival rate was significantly higher in patients with tubular carcinomas than with ductal carcinomas (96% vs 91%; P = .036) ❚Table 6❚. However, the overall survival rates for patients with tubular or ductal carcinoma were similar (89% and 85%; P = .161). An increasing percentage of tubular carcinoma did not significantly impact 10-year disease-free and overall survival rates (P = .263 and P = .404, respectively).
The 10-year disease-free survival rates for patients with carcinomas characterized by less than 70% tubularity, 70% or more tubularity and occasional nuclear grade 2, and 70% or more tubularity and pure nuclear grade 1 carcinomas were 88%, 93%, and 100%, respectively (P < .001). The overall survival rates for these 3 groups also were significantly different (P < .001). The 2 patients with carcinoma characterized by 70% or more tubularity and occasional grade 2 nuclei and with distant metastases were alive at last followup, resulting in a 100% 10-year cause-specific survival rate among patients with carcinomas with tubularity of 70% or more. The 10-year cause-specific survival rate for patients with carcinomas with less than 70% tubularity was 90%. Axillary lymph node metastases were associated significantly with lower disease-free and overall survival rates.
In multivariate analysis, tubularity-nuclear grade (P = .001; hazard ratio = 1.466) and axillary lymph node metastases (P < .001; hazard ratio = 3.260) were associated 
independently with lower disease-free survival, whereas axillary lymph node metastases were the only factor independently associated with lower overall survival (P < .001; hazard ratio = 1.884). Axillary lymph node metastases significantly impacted the survival of patients with ductal carcinomas; however, there was statistical effect in patients with tubular carcinoma. The overall survival rates in patients with ductal carcinoma with and without axillary lymph node metastases were 74% and 85% (80/94), respectively (P = .002), whereas the overall survival rates in patients with tubular carcinoma with and without axillary lymph node metastases were 86% and 92%, respectively (P = .624).
Discussion
In the present study, patients with tubular or ductal carcinoma had similar demographic and neoplasm characteristics, * Same P value for comparison of the 3 patient groups and comparison of the <70% tubularity percentage and ≥70% tubularity, occasional grade 2 nuclei groups with the ≥70% tubularity, pure grade 1 nuclei group. † P value for comparison of the <70% tubularity percentage and ≥70% tubularity, occasional grade 2 nuclei groups vs ≥70% tubularity, pure grade 1 nuclei group.
including mean age, mean maximum dimension of the carcinoma, amounts of carcinoma near the margin, distribution of margin status, rate of reexcision, and percentage of cases with axillary lymph node metastases. Except for a smaller proportion of patients with distant metastases (6% vs 15%) and a significantly higher 10-year disease-free survival rate in patients with tubular carcinoma (96% vs 91%; P = .036), outcome events in the 2 carcinoma groups were similar. These results differ from the large body of previous studies in which patients with tubular carcinoma had more favorable outcomes than did patients with grade 1 ductal carcinoma. 3, 4, 7, [9] [10] [11] [12] [13] 18, 20, [28] [29] [30] [31] [32] [33] [34] [35] There are 3 reasons why outcomes of patients with tubular and ductal carcinomas were similar. One reason is the absence of a precise definition of tubular carcinoma, including reliable morphologic criteria that separate tubular carcinoma ducts from ductal carcinoma ducts, and a precise method of calculating the percentage of tubular carcinoma ducts in a neoplasm. 18 The morphologic features that characterize tubular carcinoma are a continuum of appearances, and it is difficult to reliably set a cut point along this morphologic spectrum. This imprecision is one reason for the broad range of metastases and survival rates reported in the literature. 18 Axillary lymph node metastases rates are 6% to 12% in the studies that defined tubular carcinoma as a pure (no ductal component) neoplasm, 3, 7, 9, 32, 36 4% to 29% in studies that used a cut point of more than 90% tubular carcinoma, 20, 37, 38 0% to 20% in studies that used a cut point of more than 75% tubular carcinoma, 6, 31 and 4% to 49% in studies that did not provide a criterion. 8, 28, 33, 35, 39, 40 Approximately half of the studies reported no distant metastases in patients with tubular carcinoma, 3, 4, 7, 18, 20, 28, 29 and the remainder reported distant metastases in 3% to 12% of patients. 9, 12, 30, 31, 34 The second reason is the similarities in carcinoma and specimen dimensions, reexcision rates, and patient demographics between the 2 groups. Earlier studies, on which much of the favorable outcome of tubular carcinoma was based, had a marked disparity in carcinoma dimension between tubular and ductal carcinomas. 3, 4, 8, 10, 13 Most of the patients with ductal carcinoma had mean maximum tumor dimensions of approximately 3 cm, whereas the mean maximum dimension of tubular carcinomas was approximately 1.0 cm or less. [2] [3] [4] [5] [6] [7] [8] 10, 19, 28, 41 It is noteworthy that the mean dimension of tubular carcinoma has not changed over time. It was 0.95 cm in the present study and in the 1982 study by McDivitt et al. 8 In contrast with tubular carcinomas, the mean dimension of ductal carcinomas has decreased significantly during preceding decades to its current mean dimension of 1.1 cm. In addition, all patients in the present study were treated with breast-conserving therapy, whereas most patients with ductal carcinomas in earlier studies were treated with modified radical mastectomy. 3,4,8,10,13 The third reason underlying the similar survival rates is the improved survival of patients with ductal carcinoma. Previous authors consistently identified more favorable outcomes in patients with tubular carcinoma than in patients with ductal carcinoma, with 10-year overall survival rates of 88% to 90% for patients with tubular carcinoma compared with 70% to 80% for patients with similar stage grade 1 ductal carcinoma. 3, 10, 13 The survival rates for patients with tubular carcinoma in the present study were similar to those reported in previous studies. 3, 10, 13 However, in the present study, patients with ductal carcinoma had 5% to 20% higher survival rates than the rates reported in previous studies. Other studies also have found no significant survival differences between patients with small grade 1 ductal carcinomas and tubular carcinomas. 12, 34 The improved overall survival rate in patients with ductal carcinoma most likely reflect the advances in breast carcinoma treatment, especially prolonging the survival of patients following the development of distant metastases.
In our opinion, the previous morphologic definition of tubular carcinoma is no longer a sufficiently robust morphologic marker of a prognostically favorable subgroup in contemporary breast carcinoma patients. Looser definitions of tubular carcinoma identified patients with favorable outcomes extensively because patients with ductal carcinoma had substantially worse survival. Ductal carcinomas were, on average, much larger than those in contemporary patients, and adjuvant chemotherapy was not routine. Refined morphologic criteria that reflect these shifts in therapy and improved survival must be developed, evaluated, and implemented if morphologic feature-based surgical pathology is to continue to provide useful treatment-related and prognostic information. In this vein, Stalsberg and Hartmann 18 established the tubularity percentage factor to improve the precision of tubular carcinoma criteria. The tubularity percentage is the estimated proportion of carcinoma cells adjacent to an open lumen.
Tubularity percentage functioned as a continuous variable, providing mathematical evidence of why the visually estimated tubular carcinoma percentage is an imprecise morphologic factor. Invasive carcinomas with tubularity of 70% or more, pure grade 1 nuclei, and rare mitoses identified the prognostically favorable subset of patients with no axillary lymph node metastases and no cause-specific deaths. A minority of carcinomas with tubularity of 70% or more, occasional grade 2 nuclei, and occasional mitoses metastasized to axillary lymph nodes, but none caused a patient death. Breast carcinoma-related deaths occurred only in patients with invasive carcinomas with less than 70% tubularity. Stalsberg and Hartmann 18 also found that prominent apocrine cytoplasmic snouts were common regardless of the tubularity percentage and were not significantly associated with axillary lymph node metastases or altered causespecific survival.
We applied the tubularity percentage factor of Stalsberg and Hartmann 18 to our group of tubular and ductal carcinomas and found that only 25 (78%) of 32 invasive carcinomas that fulfilled the morphologic criteria of pure tubular carcinoma had tubularity of 70% or more. These 25 carcinomas were divided into 2 subgroups: those with occasional grade 2 nuclei (n = 16) and those with only grade 1 nuclei (n = 9). These 3 tubularity-nuclear grade groups were associated significantly with overall survival, disease-free survival, and cause-specific survival. Of the distant metastases, 86% (12/14) occurred in carcinomas with less than 70% tubularity. Breast carcinoma-related deaths were confined to this group of cases. The residual proportion (14% [2/14] ) of distant metastases cases were in the carcinoma group with tubularity of 70% or more and occasional grade 2 nuclei. Last, carcinomas with 70% or more tubularity and pure grade 1 nuclei had no axillary lymph node metastases or distant metastases.
These results strongly support the conclusions of Stalsberg and Hartmann. 18 The better prognosis of contemporary patients with grade 1 ductal carcinoma has resulted in outcomes similar to those of patients with tubular carcinoma using previous morphologic criteria. Careful examination and application of the aforementioned criteria discern a group of neoplasms that retain a distinct, more favorable outcome. Other definitions of tubular carcinoma do not guarantee the excellent prognosis.
